Analyst, Derrick Sung of Sanford Bernstein thinks JNJ has six new/recent drug launches that will collectively generate $6B in 2015 sales. The six drugs are Stelara, Simponi, Zytiga, Edurant, Xarelto (US only), and Telaprevir (ex-US, ex-Asia).
The only one of these I consider a certain blockbuster for JNJ is Xarelto.
Market Data 
Markets 
AI
